Ahead of print
Case report
Published online: 2024-01-24
Dendritic cell immunotherapy and topotecan-based metronomic chemotherapy in ovarian cancer — a case study and literature review
1
, 1, 2
, 1, 2
DOI: 10.5603/ocp.98439
Abstract
Advanced ovarian cancer is associated with an unsatisfactory prognosis. Systemic treatment toxicities adversely affect patient quality of life. Therefore, new, better therapies are needed. We present a case of a patient treated for recurrent ovarian cancer with a sequence of experimental cellular immunotherapy and chemotherapy in both classical and metronomic dosing with satisfactory results. A brief literature review on the subject of metronomic chemotherapy and immunotherapy in ovarian cancer is also provided. The addition of a dendritic vaccine to standard chemotherapy may be a valuable therapeutic option in the group of patients with platinum-sensitive recurrent ovarian cancer. Metronomic chemotherapy is not adequately researched in this setting although it appears to be a noteworthy alternative to classically dosed chemotherapy.
Keywords: ovarian cancerimmunotherapymetronomic chemotherapytopotecandendritic vaccine
References
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–249.
- Colombo N, Sessa C, du Bois A, et al. ESMO-ESGO Ovarian Cancer Consensus Conference Working Group. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol. 2019; 30(5): 672–705.
- Remesh A. Toxicities of anticancer drugs and its management. Int J Basic Clin Pharmacol. 2012; 1(1): 2.
- Maiti R. Metronomic chemotherapy. J Pharmacol Pharmacother. 2014; 5(3): 186–192.
- Cazzaniga ME, Cordani N, Capici S, et al. Metronomic Chemotherapy. Cancers (Basel). 2021; 13(9).
- Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020; 20(11): 651–668.
- Roila F, Molassiotis A, Herrstedt J, et al. participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016; 27(suppl 5): v119–v133.
- Saif MW, Diasio RB. Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005; 5(1): 27–36.
- Rapisarda A, Uranchimeg B, Sordet O, et al. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res. 2004; 64(4): 1475–1482.
- Nakashio A, Fujita N, Tsuruo T. Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway. Int J Cancer. 2002; 98(1): 36–41.
- Merritt WM, Danes CG, Shahzad MMK, et al. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther. 2009; 8(16): 1596–1603.
- European Medicines Agency. Hycamtin - Summary of product characteristics. 2023.
- Armstrong DK, Spriggs D, Levin J, et al. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. Oncologist. 2005; 10(9): 686–694.
- ten Bokkel Huinink W, Lane SR, Ross GA, et al. International Topotecan Study Group. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol. 2004; 15(1): 100–103.
- Merritt WM, Danes CG, Shahzad MMK, et al. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther. 2009; 8(16): 1596–1603.
- Taschner-Mandl S, Schwarz M, Blaha J, et al. Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence. Oncotarget. 2016; 7(3): 3571–3586.
- Hoskins P, Eisenhauer E, Beare S, et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol. 1998; 16(6): 2233–2237.
- Homesley HD, Hall DJ, Martin DA, et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol. 2001; 83(2): 394–399.
- Morris R, Alvarez RD, Andrews S, et al. Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers. Gynecol Oncol. 2008; 109(3): 346–352.
- Levy T, Inbar M, Menczer J, et al. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol Oncol. 2004; 95(3): 686–690.
- Abushahin F, Singh DK, Lurain JR, et al. Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecol Oncol. 2008; 108(1): 53–57.
- Clarke-Pearson DL, Van Le L, Iveson T, et al. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol. 2001; 19(19): 3967–3975.
- Gore M, Oza A, Rustin G, et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer. 2002; 38(1): 57–63.
- Wysocki PJ, Łobacz M, Potocki P, et al. Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer. Cancers (Basel). 2023; 15(4).
- Hamanishi J, Takeshima N, Katsumata N, et al. Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). J Clin Oncol. 2021; 39(33): 3671–3681.
- Pujade-Lauraine E, Fujiwara K, Ledermann JA, et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 2021; 22(7): 1034–1046.
- Diaz LA, Shiu KK, Kim TW, et al. KEYNOTE-177 Investigators. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022; 23(5): 659–670.
- Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013; 39(1): 38–48.
- Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol. 2012; 30: 1–22.
- Castell-Rodríguez A, Piñón-Zárate G, Herrera-Enríquez M, et al. Dendritic Cells: Location, Function, and Clinical Implications. Biology of Myelomonocytic Cells. 2017.
- Cibula D, Rob L, Mallmann P, et al. Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial. Gynecol Oncol. 2021; 162(3): 652–660.
- Kantoff PW, Higano CS, Shore ND, et al. IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363(5): 411–422.
- Moore KN, Gunderson CC, Sabbatini P, et al. A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol. 2019; 154(2): 294–301.
- Pfisterer J, Shannon CM, Baumann K, et al. AGO-OVAR 2.21/ENGOT-ov 18 Investigators. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2020; 21(5): 699–709.
- Schummer M, Drescher C, Forrest R, et al. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecol Oncol. 2012; 125(1): 65–69.
- Huang J, Chen J, Huang Q. Diagnostic value of HE4 in ovarian cancer: A meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2018; 231: 35–42.